HUTCHMED Highlights Data to be Presented at CSCO

Summary by AI BETAClose X

HUTCHMED announced that new and updated clinical data from several studies will be presented at the 2025 World Conference on Lung Cancer and the Chinese Society of Clinical Oncology Annual Meeting. Updated analysis from savolitinib's SACHI, SAVANNAH and a Phase IIIb confirmatory study in non-small cell lung cancer patients will be presented at WCLC 2025. Clinical data of HMPL-653, a novel, selective and potent CSF-1R inhibitor, from a first-in-human Phase I study in patients with tenosynovial giant cell tumor in China will be presented for the first time at the CSCO Annual Meeting 2025.

Disclaimer*

UK 100

Latest directors dealings